Science News
from research organizations

Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure

Date:
April 23, 2015
Source:
European Association for the Study of the Liver
Summary:
A novel immunotherapeutic in early development for chronic hepatitis B , has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB.
Share:
FULL STORY

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress™ 2015.

The hallmarks of a CHB cure are:

  • Elimination of HBsAg -- the surface antigen of the hepatitis B virus, and
  • HBsAg seroconversion -- which occurs when a specific antibody becomes detectable in the blood and the corresponding antigen becomes undetectable, in this case HBsAg

In the study, decrease of HBsAg and HBsAg seroconversion was achieved in 30% of TG1050-injected mice.

Earlier studies have proven that TG1050 is able to induce a robust, multi-specific and long-lasting immune response against the hepatitis B virus. These latest results, which show that TG1050 is able to decrease HBsAg and lead to anti-HBsAg seroconversion in HBV persistent mouse models, support the move to a first-in-man study and the start of clinical development.


Story Source:

Materials provided by European Association for the Study of the Liver. Note: Content may be edited for style and length.


Cite This Page:

European Association for the Study of the Liver. "Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure." ScienceDaily. ScienceDaily, 23 April 2015. <www.sciencedaily.com/releases/2015/04/150423085435.htm>.
European Association for the Study of the Liver. (2015, April 23). Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/04/150423085435.htm
European Association for the Study of the Liver. "Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure." ScienceDaily. www.sciencedaily.com/releases/2015/04/150423085435.htm (accessed May 23, 2017).

RELATED STORIES